Alpha Teknova, Inc. (TKNO) company profile

Alpha Teknova, Inc. produces critical reagents used in the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The company provides custom and catalog chemical formulations through two primary product categories: Lab Essentials and Clinical Solutions. Its product offerings include pre-poured media plates for cell cultivation, liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample processing and purification. Its customers encompass pharmaceutical and biotechnology firms, contract development and manufacturing organizations, in vitro diagnostics entities, and academic and government research institutions.

The company maintains its principal executive offices and manufacturing facilities in Hollister, California. It manufactures both research-use and good manufacturing practice grade materials to supply a customer base of more than 3,000 clients across the life sciences market.

Summary of the business section of Alpha Teknova's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price of our common stock is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 158 employees, all of which were full-time.”